Endoscopy 2021; 53(S 01): S87
DOI: 10.1055/s-0041-1724474
Abstracts | ESGE Days
ESGE Days 2021 Oral presentations
Saturday, 27 March 2021 15:00 – 15:45 New exciting technologies in upper GI endoscopy Room 5

Anti-Reflux Mucosal Ablation (ARMA) For Refractory Gastroesophageal Reflux Disease – An Interim Analysis

R Kalapala
1   Asian Institute of Gastroenterology, Medical Gastroenterology, Hyderabad, India
,
N Jagtap
1   Asian Institute of Gastroenterology, Medical Gastroenterology, Hyderabad, India
,
Z Nabi
1   Asian Institute of Gastroenterology, Medical Gastroenterology, Hyderabad, India
,
S Darisetty
2   Asian Institute of Gastroenterology, Anaesthesia, Hyderabad, India
,
H Kanakagiri
2   Asian Institute of Gastroenterology, Anaesthesia, Hyderabad, India
,
R Goud
1   Asian Institute of Gastroenterology, Medical Gastroenterology, Hyderabad, India
,
A Karaympudi
1   Asian Institute of Gastroenterology, Medical Gastroenterology, Hyderabad, India
,
DN Reddy
1   Asian Institute of Gastroenterology, Medical Gastroenterology, Hyderabad, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
 

Aims Proton pump inhibitor (PPI) refractory gastroesophageal reflux disease (GERD) is major clinical problem. Minimally invasive endoscopic therapies are being developed such as anti-reflux mucosal ablation. We describe safety and short term efficacy of ARMA in PPI-refractory GERD.

Methods In this single center, prospective single arm ongoing interventional trial evaluating the outcome of ARMA in 29 patients with PPI refractory GERD. GERD – Health Related Quality of Life Questionnaire (GERD-HRQL) evaluation was analyzed at baseline, 3 and 6 months in 20 patients and compared using ANOVA of repeated measures. Impedance-pH monitoring was performed in all patients at baseline and at 3 months in 10 patients and compared using paired t test. The p value of < 0.05 was considered as statistically significant.

Results A total of 29 patients (Mean age (SD) 39.59 (12.33) years; 10 female) underwent ARMA between September 2019 to September 2020. Mean procedure time was 29 (range 24 – 30) minutes. There were no major adverse event and all patients were discharged within 48 hours. Mean GERD-HRQL was improved from 39.90 (8.39) at baseline to 9.15 (6.66) at 3 months and 4.85 (5.17) at 6 months (p 0.001). There was significant improvement in heart burn and regurgitation score at 3 and 6 months (p 0.0001). There is trend towards improvement in DeMeester Score (41.52 (52.01) to 25.66 (43.08); p 0.415) and acid exposure time (24.48 (9.45) to 8.23 (14.68); p 0.048) from baseline to 3 months.

Tab. 1

Parameter

Baseline

3month

6 month

P value

GERD HRQL (n = 20)

39.90 (8.39)

9.15 (6.66)

4.85 (5.17)

0.001

Heart burn score (n = 20)

19.05 (11.51)

5.35 (5.78)

2.70 (2.85)

0.0001

Regurgitation score (n = 20)

20.45 (8.40)

3.45 (5.30)

2.15 (3.76)

0.0001

Acid Exposure time (n = 10)

24.48 (9.45)

8.23 (14.68)

0.048

Conclusions Our initial results shown that ARMA is safe endoscopic therapeutic option for PPI-refractory GERD with significant improvement in symptoms. Objective acid reflux parameters will be studied at 12 months.

Citation: Kalapala R, Jagtap N, Nabi Z et al. OP210 ANTI-REFLUX MUCOSAL ABLATION (ARMA) FOR REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE – AN INTERIM ANALYSIS. Endoscopy 2021; 53: S87.



Publikationsverlauf

Artikel online veröffentlicht:
19. März 2021

© 2021. European Society of Gastrointestinal Endoscopy. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany